Paradigm Capital Management Inc. NY Boosts Stake in Enovis Co. (NYSE:ENOV)

Paradigm Capital Management Inc. NY increased its stake in Enovis Co. (NYSE:ENOV - Free Report) by 2,566.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 533,200 shares of the company's stock after buying an additional 513,200 shares during the period. Enovis accounts for about 1.1% of Paradigm Capital Management Inc. NY's portfolio, making the stock its 27th largest position. Paradigm Capital Management Inc. NY owned 0.94% of Enovis worth $23,397,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ENOV. UMB Bank n.a. increased its position in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in Enovis by 19.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company's stock worth $677,000 after purchasing an additional 2,518 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Enovis during the 4th quarter worth $437,000. Tributary Capital Management LLC raised its position in Enovis by 33.9% during the 4th quarter. Tributary Capital Management LLC now owns 566,089 shares of the company's stock valued at $24,840,000 after purchasing an additional 143,258 shares in the last quarter. Finally, Park Avenue Securities LLC raised its position in Enovis by 12.5% during the 4th quarter. Park Avenue Securities LLC now owns 11,988 shares of the company's stock valued at $526,000 after purchasing an additional 1,333 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ENOV. JMP Securities cut their price target on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Needham & Company LLC dropped their target price on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Canaccord Genuity Group reduced their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $58.00.

Enovis Stock Down 2.3%

Enovis stock traded down $0.76 during midday trading on Friday, reaching $31.61. The company's stock had a trading volume of 692,977 shares, compared to its average volume of 787,077. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market capitalization of $1.81 billion, a P/E ratio of -14.43 and a beta of 1.79. The stock's 50-day simple moving average is $34.73 and its 200-day simple moving average is $41.06. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $51.00.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The company had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. Enovis's revenue for the quarter was up 8.2% on a year-over-year basis. During the same period last year, the business earned $0.50 EPS. On average, sell-side analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.